- Home
- AARD vs OPRX Comparison
AARD vs OPRX Comparison
Compare AARD & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AARD | OPRX |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | 105 |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.7M | 137.3M |
| IPO Year | 2025 | 2008 |
Fundamental Metrics
Financial Performance| Metric | AARD | OPRX |
|---|---|---|
| Price | $5.56 | $7.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $15.29 | ★ $16.67 |
| AVG Volume (30 Days) | ★ 125.5K | 120.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 43.11 | ★ 124.55 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $109,429,000.00 |
| Revenue This Year | N/A | $3.88 |
| Revenue Next Year | N/A | $8.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.78 |
| 52 Week Low | $3.35 | $4.54 |
| 52 Week High | $17.94 | $22.25 |
Technical Indicators
Market Signals| Indicator | AARD | OPRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 50.68 |
| Support Level | $5.47 | $6.99 |
| Resistance Level | $6.01 | $8.30 |
| Average True Range (ATR) | 0.55 | 0.38 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 59.53 | 45.64 |
Price Performance
Historical ComparisonAbout AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.